Amneal Pharmaceuticals, Inc.
For the period ended Sep 30, 2026. Filed Nov 9, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 9, 2026
AMRX$21.38+0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Comprehensive (Loss) Income
| Three Months Ended September 30, | Nine Months Ended September 30, | |||
|---|---|---|---|---|
| 2026 | 2025 | 2026 | 2025 | |
| Net income | $12,306 | $18,132 | $159,920 | $78,360 |
| Less: Net income attributable to non-controlling interests | (19,762) | (15,763) | (47,458) | (41,379) |
| Net (loss) income attributable to Amneal Pharmaceuticals, Inc. before accretion of redeemable non-controlling interests | (7,456) | 2,369 | 112,462 | 36,981 |
| Accretion of redeemable non-controlling interests | (14,239) | — | (14,239) | — |
| Net (loss) income attributable to Amneal Pharmaceuticals, Inc. | (21,695) | 2,369 | 98,223 | 36,981 |
| Other comprehensive (loss) income: | ||||
| Foreign currency translation adjustments arising during the period | (3,428) | (9,088) | (13,332) | (15,648) |
| Unrealized gain (loss) on cash flow hedge, net of tax of $0 | 17,563 | (3,526) | 28,019 | (23,011) |
| Reclassification of cash flow hedge to earnings, net of tax of $0 | 2,942 | 4,162 | 8,730 | (1,714) |
| Other, net of tax of $0 | 505 | — | 4,228 | — |
| Other comprehensive income (loss) attributable to Amneal Pharmaceuticals, Inc. | 17,582 | (8,452) | 27,645 | (40,373) |
| Comprehensive (loss) income attributable to Amneal Pharmaceuticals, Inc. | $(4,113) | $(6,083) | $125,868 | $(3,392) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.